Jonina S. Gudmundsdottir

Jonina S. Gudmundsdottir

Auto-generated profile, based on publicly available information

Jonina S. Gudmundsdottir

Department of Pharmacy, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2019 in mBio
Verified
Journal Article
Open access
PDF file
MKMichael Knopp
Michael Knopp
JGJonina S. Gudmundsdottir
Jonina S. Gudmundsdottir
TNTobias Nilsson
Tobias Nilsson
FKFinja König
Finja König
OWOmar Warsi
Omar Warsi
DADan I. Andersson
Dan I. Andersson
De novo gene origination from nonfunctional DNA sequences was long assumed to be implausible. However, recent studies have shown that large fractions of genomic noncoding DNA are transcribed and translated, potentially generating new genes. Experimental validation of this process so far has been limited to comparative genomics, in vitro selections, or partial randomizations. Here, we describe selection of novel peptides in vivo using fully random synthetic expression libraries. The peptides confer aminoglycoside resistance by inserting into the bacterial membrane and thereby partly reducing membrane potential and decreasing drug uptake. Our results show that beneficial peptides can be selected from random sequence pools in vivo and support the idea that expression of noncoding sequences could spark the origination of new genes.

7 January 2021 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MKMichael Knopp
Michael Knopp
ABArianne M. Babina
Arianne M. Babina
JGJónína S. Gudmundsdóttir
Jónína S. Gudmundsdóttir
MDMartin V. Douglass
Martin V. Douglass
MTM. Stephen Trent
M. Stephen Trent
DADan I. Andersson
Dan I. Andersson
Antibiotic resistance is a rapidly increasing medical problem that severely limits the success of antibiotic treatments, and the identification of resistance determinants is key for surveillance and control of resistance dissemination. Horizontal transfer is the dominant mechanism for spread of resistance genes between bacteria but little is known about the original emergence of resistance genes. Here, we examined experimentally if random sequences can generate novel antibiotic resistance determinants de novo. By utilizing highly diverse expression libraries encoding random sequences to select for open reading frames that confer resistance to the last-resort antibiotic colistin in Escherichia coli, six de novo colistin resistance conferring peptides (Dcr) were identified. The peptides act via direct interactions with the sensor kinase PmrB (also termed BasS in E. coli), causing an activation of the PmrAB two-component system (TCS), modification of the lipid A domain of lipopolysaccharide and subsequent colistin resistance. This kinase-activation was extended to other TCS by generation of chimeric sensor kinases. Our results demonstrate that peptides with novel activities mediated via specific peptide-protein interactions in the transmembrane domain of a sensory transducer can be selected de novo, suggesting that the origination of such peptides from non-coding regions is conceivable. In addition, we identified a novel class of resistance determinants for a key antibiotic that is used as a last resort treatment for several significant pathogens. The high-level resistance provided at low expression levels, absence of significant growth defects and the functionality of Dcr peptides across different genera suggest that this class of peptides could potentially evolve as bona fide resistance determinants in natura.

11 December 2021 in EBioMedicine
Verified
Journal Article
Open access
JGJónína S. Guðmundsdóttir
Jónína S. Guðmundsdóttir
EFElizabeth G.A. Fredheim
Elizabeth G.A. Fredheim
CKCatharina I.M. Koumans
Catharina I.M. Koumans
JHJoachim Hegstad
Joachim Hegstad
PTPo-Cheng Tang
Po-Cheng Tang
PJPål J. Johnsen
Pål J. Johnsen
Understanding drivers of antibiotic resistance evolution is fundamental for designing optimal treatment strategies and interventions to reduce the spread of antibiotic resistance. Various cytotoxic drugs used in cancer chemotherapy have antibacterial properties, but how bacterial populations are affected by these selective pressures is unknown. Here we test the hypothesis that the widely used cytotoxic drug methotrexate affects the evolution and selection of antibiotic resistance. First, we determined methotrexate susceptibility (IC90) and selective abilities in a collection of Escherichia coli and Klebsiella pneumoniae strains with and without pre-existing trimethoprim resistance determinants. We constructed fluorescently labelled pairs of E. coli MG1655 differing only in trimethoprim resistance determinants and determined the minimum selective concentrations of methotrexate using flow-cytometry. We further used an experimental evolution approach to investigate the effects of methotrexate on de novo trimethoprim resistance evolution. We show that methotrexate can select for acquired trimethoprim resistance determinants located on the chromosome or a plasmid. Additionally, methotrexate co-selects for genetically linked resistance determinants when present together with trimethoprim resistance on a multi-drug resistance plasmid. These selective effects occur at concentrations 40- to >320-fold below the methotrexate minimal inhibitory concentration. Our results strongly suggest a selective role of methotrexate for virtually any antibiotic resistance determinant when present together with trimethoprim resistance on a multi-drug resistance plasmid. The presented results may have significant implications for patient groups strongly depending on effective antibiotic treatment. PJJ was supported by 10.13039/100007465 UiT The Arctic University of Norway and the Northern Norway Regional Health Authority (SFP1292–16/HNF1586–21) and JPI-EC-AMR (Project 271,176/H10). DIA was supported by the 10.13039/501100004359 Swedish Research Council (grant 2017–01,527). The publication charges for this article have been funded by a grant from the publication fund of UiT The Arctic University of Norway.

12 November 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
JGJónína S. Gudmundsdóttir
Jónína S. Gudmundsdóttir
EFElizabeth G. A. Fredheim
Elizabeth G. A. Fredheim
CKCatharina I. M. Koumans
Catharina I. M. Koumans
JHJoachim Hegstad
Joachim Hegstad
PTPo-Cheng Tang
Po-Cheng Tang
PJPål J. Johnsen
Pål J. Johnsen
Understanding drivers of antibiotic resistance evolution is fundamental for designing optimal treatment strategies and interventions to reduce the spread of antibiotic resistance. Various cytotoxic drugs used in cancer chemotherapy have antibacterial properties, but how bacterial populations are affected by these selective pressures is unknown. Here we test the hypothesis that the widely used cytotoxic drug methotrexate affects the evolution and selection of antibiotic resistance through the same mechanisms as the antibiotic trimethoprim. We show that methotrexate can select for trimethoprim resistance determinants located on the chromosome or a plasmid in clinical strains of Escherichia coli . Additionally, methotrexate can co-select for virtually any antibiotic resistance determinant when present together with trimethoprim resistance on a multidrug-resistance clinical plasmid. These selective effects occur at concentrations 40- to >320-fold below the methotrexate minimal inhibitory concentration for E. coli , suggesting a selective role of methotrexate chemotherapy for antibiotic resistance in patients that strongly depend on effective antibiotic treatment. Significance statement: The presented data show that methotrexate has the potential to select for virtually any given antibiotic resistance gene when genetically linked to trimethoprim resistance. This study highlights the need for increased awareness of the presence of acquired antibiotic resistance determinants in the gut of patients with impaired immunity undergoing methotrexate treatment to preserve the effects of downstream antibiotic treatments.